LIDODERM (lidocaine) by Teikoku Seiyaku is clinical pharmacology pharmacodynamics lidocaine is an amide-type local anesthetic agent and is suggested to stabilize neuronal membranes by inhibiting the ionic fluxes required for the initiation and conduction of impulses. First approved in 1999.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
LIDODERM is a topical lidocaine 5% patch approved in 1999 for localized pain relief, containing an amide-type local anesthetic that stabilizes neuronal membranes to inhibit pain impulse conduction. The patch delivers minimal systemic absorption (3% of applied dose), producing local analgesia without complete sensory block, making it suitable for postherpetic neuralgia and other localized pain conditions. Lidocaine penetrates intact skin to concentrations that produce therapeutic topical effect while maintaining a safety profile with negligible systemic exposure.
Product approaching loss of exclusivity with modest Medicare spend ($3M) and low claim volume, signaling a mature market with declining team investment.
CLINICAL PHARMACOLOGY Pharmacodynamics Lidocaine is an amide-type local anesthetic agent and is suggested to stabilize neuronal membranes by inhibiting the ionic fluxes required for the initiation and conduction of impulses. The penetration of lidocaine into intact skin after application of…
Worked on LIDODERM at Teikoku Seiyaku? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Amide Local Anesthetic
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Localized Injection of Lidocaine Via the Middle Meningeal Artery for Headache Treatment
Study to Assess Adverse Events and How Effective NOA LIFT is Compared to JUVÉDERM VOLIFT With Lidocaine for the Correction of Nasolabial Folds in Adults
Study to Evaluate the Safety of Retreatment With Restylane® Lyft With Lidocaine for Augmentation of the Chin Region
Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias
Lidocaine for LESS Postoperative Shoulder Pain Alleviation
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moLIDODERM offers limited career advancement opportunity given approaching LOE, minimal linked job openings (0), and declining organizational investment in the franchise. Roles on this product typically focus on transition management, generic containment, and cost-based strategies rather than growth or innovation.